GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

XenoPort is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in partnership with Astellas Pharma Inc. and GSK. XenoPort's product candidates are being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity related to spinal cord injury and Parkinson's disease. To learn more about XenoPort, please visit the Web site at www.XenoPort.com.

GlaxoSmithKline cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008.

XenoPort Forward-Looking Statement

This press release contains "forward-looking" statements, including, without limitation, all statements related to the PDUFA goal date extension. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort' s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the uncertainty of the FDA approval process and other regulatory requirements; XenoPort' s dependence on its current and additional collaborative partners; and the therapeutic and commercial value of the company' s compounds. These and other risk factors are discussed under the heading "Risk Factors " in XenoPort' s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2009. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

SOURCE: XenoPort, Inc.

GlaxoSmithKline Enquiries: 
UK Media enquiries: 
Philip Thomson, (020) 8047 5502 
Claire Brough, (020) 8047 5502 
Alexandra Harrison, (020) 8047 5502 
or 
US Media enquiries: 
Kevin Colgan, 919-483-2839 
Holly Russell, 919-483-2839 
Mary Anne Rhyne, 919-483-2839 
Sarah Alspach, 215-751-7709 
or 
European Analyst/Investor enquiries: 
David Mawdsley, (020) 8047 5564 
Sally Ferguson, (020) 8047 5543 
Gary Davies, (020) 8047 5503 
or 
US Analyst/Investor enquiries: 
Tom Curry, 215-751-5419 
Jen Baxter, 215-751-7002 
or 
XenoPort Enquiries: 
XenoPort Analyst/Investor and Media enquiries: 
Jackie Cossmon, 408-616-7220

GSK has reported a turnover of GBP6.76 billion for the third quarter of 2009 compared to GBP5.88 billion for the same period of 2008.

For the first nine months ended September 30, 2009, the company has reported a profit of GBP4 billion, or 76.4 pence per diluted share, compared to GBP3.69 billion, or 68.7 pence per diluted share, for the first nine months ended September 30, 2008.

Operating profit for the first nine-month period of 2009 was GBP5.98 billion compared to GBP5.56 billion for the same period of 2008.

For the first nine months of 2009, the turnover was GBP20.27 billion compared to GBP17.44 billion for the same period of 2008.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

In a press release on November 02, U.S. Raytheon Completes Free Flight of Joint Standoff Weapon Extended Range

NAVAL AIR WARFARE CENTER WEAPONS DIVISION SEA TEST RANGE, Calif., Nov 02, 2009 Raytheon Company (NYSE: RTN) and the U.S. Navy completed the first free-flight demonstration of the Joint Standoff Weapon Extended Range air-to-surface precision guided missile.

About Raytheon Company

Raytheon Company, with 2008 sales of $23.2 billion, is a technology and innovation leader specializing in defense, homeland security and other government markets throughout the world. With a history of innovation spanning 87 years, Raytheon provides state-of-the-art electronics, mission systems integration and other capabilities in the areas of sensing; effects; and command, control, communications and intelligence systems, as well as a broad range of mission support services. With headquarters in Waltham, Mass., Raytheon employs 73,000 people worldwide.

-- November 02, 2009 AT&T Inc. (NYSE: T) trading at $25.52 on a volume of 10.65M shares

In a press release on November 02, Edwards Lifesciences and DexCom Announce Receipt of CE Mark for Glucose Monitoring System

IRVINE, CA and SAN DIEGO, CA, Nov 02, 2009 AT&T Brings 3G Mobile Broadband Network to More Georgians

Local Wireless Network Upgrades Extend Access to Advanced Products, Services and Applications

ATLANTA, Nov 02, 2009 AT&T* today announced the availability of its 3G mobile broadband network in more cities across Georgia including Augusta, North Augusta and Aiken (Sc), Statesboro, Macon, Warner Robins, Perry, Fort Valley and Valdosta. With the addition of these newly added markets, AT&T added more than 1,400 square miles of new mobile broadband coverage in the state.

AT&T's 3G mobile broadband network now includes more than 300 square miles of new 3G coverage across Augusta, North Augusta and Aiken, Sc.; more than 750 square miles of new 3G coverage across Macon, Warner Robins, Perry and Fort Valley; more than 70 square miles of new 3G coverage across Statesboro; and more than 300 square miles of new 3G coverage across Valdosta.

About AT&T

AT&T Inc. (NYSE: T) is a premier communications holding company. Its subsidiaries and affiliates - AT&T operating companies - are the providers of AT&T services in the United States and around the world. With a powerful array of network resources that includes the nation's fastest 3G network, AT&T is a leading provider of wireless, Wi-Fi, high speed Internet and voice services. AT&T offers the best wireless coverage worldwide, offering the most wireless phones that work in the most countries. It also offers advanced TV services under the AT&T U-verse(SM) and AT&T | DIRECTV(SM) brands. The company's suite of IP-based business communications services is one of the most advanced in the world. In domestic markets, AT&T's Yellow Pages and YELLOWPAGES.COM organizations are known for their leadership in directory publishing and advertising sales. In 2009, AT&T again ranked No. 1 in the telecommunications industry on FORTUNE(R) magazine's list of the World's Most Admired Companies.

-- November 02, 2009 GlaxoSmithKline PLC (NYSE: GSK) trading at $40.78 on a volume of 951,472 shares.

In a press release out on November 02, Human Genome Sciences and GlaxoSmithKline announce positive results in second of two Phase 3 trials of belimumab in systemic lupus erythematosus

ROCKVILLE, MD, LONDON, UK and MISSISSAUGA, ON Nov. 2, 2009 Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that belimumab met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care. Study results also showed that belimumab was generally well tolerated, as demonstrated by a similar rate of discontinuations due to adverse events across treatment groups, with overall adverse event rates comparable between belimumab and placebo treatment groups.

About GlaxoSmithKline

GlaxoSmithKline's collaboration with HGS is led by its GSK Biopharm R&D division, which employs novel approaches to harness the therapeutic potential of biopharmaceuticals for the benefit of patients with serious autoimmune disease. This innovative research is one way GSK - one of the world's leading research-based pharmaceutical and healthcare companies - can deliver on its commitment to improve the quality of human life by enabling people to do more, feel better and live longer. For more information, visit GlaxoSmithKline on the World Wide Web atwww.gsk.com.

-- November 02, 2009 Lender Processing Services, Inc. (NYSE: LPS) last at $40.23 a volume of 193,870 shares

In a press release out on November 02, LPS Announces Acquisition of Auction Solutions Provider for Residential REO Properties

Auction Component Expands Servicers' REO Disposition Options and Complements Existing LPS Asset Management Offerings

JACKSONVILLE, Fla., Nov 02, 2009 Lender Processing Services, Inc. (NYSE: LPS), a leading provider of integrated technology and services to the mortgage and real estate industries, today announced its acquisition of Rising Tide Auctions, which is known for its market-leading property auction expertise and innovative property auction strategy. The acquisition will expand the asset management offerings of LPS and allow the company to provide comprehensive property auction solutions to help servicers minimize REO timelines and reduce costs. Furthermore, real estate buyers and investors will be provided with the ability to purchase individual or multiple bank-owned properties directly from the nation's leading REO disposition service provider.

About Lender Processing Services

Lender Processing Services, Inc. (LPS) is a leading provider of integrated technology and services to the mortgage and real estate industries. LPS offers solutions that span the mortgage continuum, including lead generation, origination, servicing, workflow automation (LPS Desktop(TM)) portfolio retention and default, augmented by the company's award-winning customer support and professional services. Approximately 50 percent of all U.S. mortgages by volume are serviced using LPS' Mortgage Servicing Package (MSP). In fact, many of the nation's top servicers rely on MSP, including eight of the top 10 and 14 of the top 20. LPS also offers proprietary mortgage and real estate data and analytics for the mortgage and capital markets industries. For more information about LPS, please visit www.lpsvcs.com.

-- November 02, 2009 Wipro Limited (NYSE:WIT) last at $17.48 on a volume of 377,592 shares

In a press release out on November 02, Wipro is a Leader among Oracle Services Providers

IT major "is strongest in technical elements of Oracle Implementations, but through Wipro Consulting, it also has a growing focus on process and transformational consulting"

BANGALORE, India, Nov 02, 2009 Wipro Technologies, the global IT services business of Wipro Limited (NYSE:WIT), announced that it has been cited by Forrester Research, Inc., an independent research firm, as a leader among Oracle Services Providers in a report in October 2009 titled "The Forrester Wave: Oracle Implementation Providers, Q4 2009." Forrester evaluated fourteen global vendors providing Oracle services across 60 criteria. The report notes that "Wipro is strongest at the technical elements of Oracle implementations, but through Wipro Consulting, it also has a growing focus on process and transformational consulting."

About Wipro

Wipro Technologies, a division of Wipro Limited (NYSE:WIT) is the first PCMM Level 5 and SEI CMM Level 5 certified global IT services organization. Wipro Technologies was recently assessed at Level 5 for CMMI V 1.2 across offshore and onsite development centers. Wipro is one of the largest product engineering and support service providers worldwide. Wipro provides comprehensive research and development services, IT solutions and services, including systems integration, information systems outsourcing, package implementation, software application management, and datacenter managed services to corporations globally. In the Indian market, Wipro is a leader in providing IT solutions and services for the corporate segment in India, offering system integration, network integration, software solutions and IT services.

-- November 02, 2009 The Bank of New York Mellon Corporation (NYSE: BK) trading at $27.08 on a volume of 2.74M shares

In a press release out on November 02, BNY Mellon Appointed as Depositary Bank by Tatung Company, Ltd. for Its Global Depositary Receipt Offering

NEW YORK, Nov 02, 2009 BNY Mellon, the global leader in asset management and securities servicing, has been selected by Tatung Company, Ltd. (Tatung) as depositary for its global depositary share (GDS) program. The International GDSs and Rule 144A GDSs are listed on the Luxembourg Stock Exchange and trade on the Euro MTF market and are quoted on the International Order Book (IOB) of the London Stock Exchange under the symbols, "TAT" and "TAT1," respectively. The common shares are listed on the Taiwan Stock Exchange under the stock code "2371." Each Tatung GDS represents 20 common shares. Tatung GDSs and common shares have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the U.S. (absent registration or an applicable exemption from the registration requirements).

Tatung designs and manufactures digital consumer products, including LCD TVs, network-connected devices, and home appliances. The company also provides system integration services and is engaged in industrial businesses such as wire & cable, optical fiber cables, gas insulated switchgears, motors, generators and transformers. Tatung focuses especially on the development of advanced technologies and has a global network of operations in 12 countries.

About BNY Mellon

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK). BNY Mellon is a global financial services company focused on helping clients manage and service their financial assets, operating in 34 countries and serving more than 100 markets. The company is a leading provider of financial services for institutions, corporations and high-net-worth individuals, providing superior asset management and wealth management, asset servicing, issuer services, clearing services and treasury services through a worldwide client-focused team. It has $22.1 trillion in assets under custody and administration and $966 billion in assets under management, services $11.9 trillion in outstanding debt and processes global payments averaging $1.6 trillion per day. Additional information is available at bnymellon.com.

www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com

www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

CONTACT: PicksThatMove.com e-mail: Info@picksthatmove.com WWW: http://www.picksthatmove.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

http://www.reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Introduction

This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark GlaxoSmithKline's performance against key rivals in the prescription pharmaceutical sector

*Assess the threat posed by generic competition to GlaxoSmithKline's core prescription pharmaceutical business

*Analyze the future strategic direction of GSK, namely an enhanced vaccine offering, geographic diversification and increased biologics presence

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

GlaxoSmithKline: PharmaVitae forecasts at a glance 8

Strategic insight 9

Introduction 9

Analysis of sales performance 2002-08 9

Analysis of sales performance 2008-14 10

Outlook 14

SWOT analysis 16

Strengths 17

Weaknesses 18

Opportunities 18

Threats 20

TABLE OF CONTENTS 22

Table of figures 24

Chapter 3 Quarterly news update 25

Product developments 25

Deals and alliances 27

Product deals 27

Technology deals 32

M&A activity 33

Company announcements 33

Future product milestones 35

Chapter 4 Company introduction 38

Key findings 38

Background 39

M&A history 39

Glaxo and Wellcome 39

Glaxo Wellcome 39

Smith Kline and Beecham 39

SmithKline Beecham 40

Key historical drug launches by component GSK companies 41

M&A strategy 41

R&D overview 44

Chapter 5 Company sales 46

Key findings 46

Prescription pharmaceutical sales and growth rate analysis, 2002-14 47

Product analysis 49

Product analysis, 2002-08 50

Product analysis, 2008-14 53

Therapy area analysis 56

Geographic analysis 59

Launch/core/expiry analysis 61

Explanation of launch/core/expiry analysis 61

Launch analysis, 2008-14 62

Core analysis, 2008-14 65

Expiry analysis, 2008-14 66

Launch/core/expiry configuration, 2008-14 68

Molecule type analysis 69

Externalization analysis 73

Chapter 6 Company financials 76

Key findings 76

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 77

Operating costs and profit analysis 78

Operating costs and profit analysis, 2002-08 79

Operating cost ratio and profit margin analysis, 2002-08 80

Operating cost ratio and profit margin analysis, 2008-14 81

Operating costs and profit analysis, 2008-14 82

Chapter 7 Key products and competitors 83

Overview 83

Respiratory 84

Seretide/Advair 84

Overview 84

Sales forecast 85

Beyond Advair 87

Overview 87

Sales forecast 88

Infectious diseases 89

Cervarix 89

Overview 89

Sales forecast 90

Valtrex 93

Overview 93

Sales forecast 94

Oncology 95

Tykerb/Tyverb 95

Overview 95

Sales forecast 96

Genitourinary 98

Duodart 98

Overview 98

Sales forecast 99

Central Nervous system 100

Almorexant 100

Overview 100

Sales forecast 101

Lamictal 102

Overview 102

Sales forecast 103

Imigran/Imitrex 105

Overview 105

Sales forecast 106

Endocrinology 108

Avandia 108

Overview 108

Sales forecast 109

Chapter 8 Appendix 112

R&D pipeline 112

Abbreviations 115

Exchange rates 116

About Datamonitor 117

About Datamonitor Healthcare 117

Datamonitor consulting 117

Disclaimer 119

LIST OF TABLES

Table 1: GlaxoSmithKline - PharmaVitae forecasts at a glance 8

Table 2: GlaxoSmithKline vaccine sales ($m), 2008-14 13

Table 3: GlaxoSmithKline key product developments, 2009 25

Table 4: GlaxoSmithKline product deals and alliances, 2009 27

Table 5: GlaxoSmithKline technology deals and alliances, 2009 32

Table 6: GlaxoSmithKline M&A activity, 2009 33

Table 7: GlaxoSmithKline company announcements, 2009 33

Table 8: GlaxoSmithKline future product milestones, 2009-11 35

Table 9: GlaxoSmithKline product portfolio overview ($m), 2002-08 50

Table 10: GlaxoSmithKline product portfolio overview ($m), 2008-14 53

Table 11: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2008-14 57

Table 12: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2008-14 60

Table 13: GlaxoSmithKline launch portfolio overview ($m), 2008-14 62

Table 14: GlaxoSmithKline core portfolio overview ($m), 2008-14 65

Table 15: GlaxoSmithKline expiry portfolio overview ($m), 2008-14 66

Table 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2008-14 70

Table 17: GlaxoSmithKline vaccine sales ($m), 2008-14 71

Table 18: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2008-14 74

Table 19: Total GlaxoSmithKline sales by business unit ($m), 2002-08 77

Table 20: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-08 79

Table 21: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2002-08 80

Table 22: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2008-14 81

Table 23: GlaxoSmithKline operating revenue/cost analysis ($m), 2008-14 82

Table 24: GlaxoSmithKline Key products overview 83

Table 25: Seretide/Advair: overview 84

Table 26: Seretide/Advair: sales forecast ($m), 2008-14 85

Table 27: Beyond Advair: overview 87

Table 28: Beyond Advair: sales forecast ($m), 2008-14 88

Table 29: Cervarix: overview 89

Table 30: Cervarix: sales forecast ($m), 2008-14 90

Table 31: Valtrex: overview 93

Table 32: Valtrex: sales forecast ($m), 2008-14 94

Table 33: Tykerb/Tyverb: overview 95

Table 34: Tykerb/Tyverb: sales forecast ($m), 2008-14 96

Table 35: Duodart: overview 98

Table 36: Duodart: sales forecast ($m), 2008-14 99

Table 37: Almorexant: overview 100

Table 38: Almorexant: sales forecast ($m), 2008-14 101

Table 39: Lamictal: overview 102

Table 40: Lamictal: sales forecast ($m), 2008-14 103

Table 41: Imigran/Imitrex: overview 105

Table 42: Imigran/Imitrex: sales forecast ($m), 2008-14 106

Table 43: Avandia: overview 108

Table 44: Avandia: sales forecast ($m), 2008-14 109

Table 45: GlaxoSmithKline's R&D pipeline (Phase I-registration) 112

Table 46: Exchange rates, 2009 116

LIST OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: GlaxoSmit6thKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: GlaxoSmithKline's financial performance ($m), 2002-14 7

Figure 4: GlaxoSmithKline launch/core/expiry configuration ($m), 2002-08 9

Figure 5: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 10

Figure 6: GlaxoSmithKline prescription pharmaceutical sales growth by molecule type ($m), 2008-14 12

Figure 7: GlaxoSmithKline SWOT analysis 16

Figure 8: M&A/divestment history 40

Figure 9: GlaxoSmithKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 47

Figure 10: Key product sales ($m), 2002-14 49

Figure 11: GlaxoSmithKline key sales growth drivers and resistors ($m), 2002-08 52

Figure 12: GlaxoSmithKline key sales growth drivers and resistors ($m), 2008-14 55

Figure 13: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2002-14 56

Figure 14: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2002-14 59

Figure 15: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 68

Figure 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2002-14 69

Figure 17: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2002-14 73

Figure 18: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-14 78

To order this report:

GlaxoSmithKline plc: PharmaVitae Profile

http://www.reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker